Siplizumab u T1DM (DESIGNATE)
Studie pro zjištění signatury řízené dávky fenotypu T buněk se siplizumabem u diabetes mellitus 1. typu (ITN095AI)
This is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis. within 18 months of V0. Participants will be randomized 1:1:1:1 to one of four possible siplizumab dosing arms. All dosing arms will receive weekly siplizumab doses for a total of 12 weeks. After the completion of treatment, participants will undergo follow-up visits at weeks 12, 24, 36 and 52 which include longitudinal MMTTs. If indicated, participants will enter into long-term safety monitoring for up to an additional 48 weeks. Blood samples for mechanistic analyses will be obtained during the treatment phase and thereafter. Adults aged 18- 45 will be enrolled initially at the study sites.
The primary objective is to identify a safe, metabolically favorable, dosing regimen for siplizumab in patients with type 1 diabetes that induces changes in T cell phenotypes observed with alefacept therapy in new-onset T1DM.
The secondary objectives are to:
- Assess the safety profile of siplizumab in recently diagnosed T1DM.
- Assess the effects of siplizumab on residual beta cell function in recently diagnosed T1DM participants.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 2
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- University of Colorado School of Medicine: Barbara Davis Center for Diabetes
-
-
Iowa
-
Iowa City, Iowa, Spojené státy, 52242
- University of Iowa Children's Hospital: Department of Pediatrics, Pediatric Endocrinology and Diabetes
-
-
New York
-
New York, New York, Spojené státy, 10032
- Columbia University Medical Center: Naomi Berrie Diabetes Center
-
-
Texas
-
Dallas, Texas, Spojené státy, 75390
- University of Texas Southwestern Medical Center: Department of Internal Medicine, Division of Endocrinology
-
-
Washington
-
Seattle, Washington, Spojené státy, 98101
- Benaroya Research Institute at Virginia Mason: Diabetes Research Program
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Ability to provide informed consent (parental permission and informed assent of minor, if applicable).
-
Male or female between 8 to 45 years of age.
-
Diagnosis of T1DM within 18 months (550 days) of enrollment (V0).
-
Positive for at least one diabetes-related autoantibody, including:
- Glutamate decarboxylase (GAD-65),
- Insulin, if obtained within 10 days of the onset of exogenous insulin therapy,
- Insulinoma antigen-2 (IA-2), or
- Zinc transporter-8 (ZnT8).
-
Peak stimulated C-peptide level > 0.15 nmol/L following a MMTT conducted ≥ 21 days from diagnosis and within 37 days of enrollment (V0).
-
Completion of a SARS-CoV-2 vaccination, according to current CDC recommendations and FDA approval(s) or emergency use authorization(s). If the participant requires administration of vaccine(s) to meet eligibility requirements, they must complete the vaccination series at least 2 weeks prior to enrollment (V0).
Exclusion Criteria:
-
1. Use of investigational drugs within 24 weeks of participation with the exception of any vaccine for the prevention of SARS-CoV-2 infection and emergency use authorization medications for treating SARS-CoV-2.
-
Severe reaction or anaphylaxis to humanized monoclonal antibodies.
-
Inability to complete a mixed meal tolerance test:
- History of significant allergy (e.g., anaphylaxis) to milk or soy proteins.
- Inability to disable hybrid closed loop system.
-
History of recent (within 180 days of V0) or ongoing uncontrolled bacterial, viral, fungal or other opportunistic infections, including:
- Human immunodeficiency virus (HIV),
- Current or prior infection with hepatitis B (HBV), as indicated by positive HBsAg or positive HBcAb,
- Current or prior hepatitis C (HCV), unless treated with anti-viral therapy with achievement of a sustained virologic response (undetectable viral load 12 weeks after cessation of therapy),
- Positive QuantiFERON-TB Gold or QuantiFERON-TB Gold Plus tests. PPD or T-SPOT®.TB may be substituted for the QuantiFERON-TB Gold or QuantiFERON-TB Gold Plus tests,
- Active infection with EBV as detected by PCR or serology at the screening visit (V-1),
- Active infection with cytomegalovirus (CMV) as detected by PCR or serology at the screening visit (V-1),
-
Positive molecular testing of SARS-CoV-2 within 30 days of V-1.
-
Any of the following laboratory abnormalities confirmed by repeat tests at least 1 week apart:
- White blood count (WBC) < 3 x 103/μL;,
- CD 3+ CD4+, T cell count below the lower limit of normal,
- Platelet count < 150,000 /μL,
- Hemoglobin < 10 g/dL,
- ALT ≥ 2x upper limit of normal (ULN) or
- AST ≥ 2x ULN
- Serum creatinine >1.5x ULN in adults or >ULN in pediatrics.
- Absolute lymphocyte count (ALC) below the LLN.
-
Prior or current treatment that is known to alter the natural history of T1DM or immunologic status, including high dose inhaled, extensive topical or systemic glucocorticoids.
-
Current or prior (within last 14 days of the V-1 MMTT) use of any medication known to influence glucose tolerance (e.g., atypical antipsychotics, diphenylhydantoin, thiazide, or other potassium-depleting diuretics, β-adrenergic blockers, niacin).
-
Current or prior (within the last 30 days of the V-1 MMTT) use of non-insulin medications to treat insulin resistance or elevated glucose levels.
-
Previous or current diagnosis of malignancy.
-
History of bone marrow transplantation, solid organ transplantation, or primary immunodeficiencies.
-
History or diagnoses of other autoimmune diseases with the exception of stable thyroid or celiac disease.
-
History of significant cardiovascular disease.
-
Vaccination with a live attenuated vaccine (e.g., varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, bacillus Calmette- Guérin, and smallpox) within 30 days of V0.
-
Women of child-bearing potential who are unwilling to use a medically acceptable form of contraception from 14 days prior to V0 until study Week 52.
-
Women who are pregnant, lactating, or planning on pregnancy during the study.
-
Current, diagnosed mental illness (e.g., severe depression), current diagnosed or self-reported drug, or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.
-
Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Adults with T1D 0.08 mg/kg SQ dose
Cohort 1 Group1: 0.08 mg/kg SQ dose for a total of 12 weeks |
Weekly siplizumab doses for a total of 12 weeks
Ostatní jména:
|
|
Experimentální: Adults with T1D 0.12 mg/kg SQ dose
Cohort 1 Group 2: 0.12 mg/kg SQ dose for a total of 12 weeks |
Weekly siplizumab doses for a total of 12 weeks
Ostatní jména:
|
|
Experimentální: Adults with T1D 0.18 mg/kg SQ dose
Cohort 1 Group 3:0.18 mg/kg SQ dose for a total of 12 weeks |
Weekly siplizumab doses for a total of 12 weeks
Ostatní jména:
|
|
Experimentální: Adults with T1D 0.22 mg/kg SQ dose
Cohort 1 Group 4: 0.22 mg/kg SQ dose for a total of 12 weeks |
Weekly siplizumab doses for a total of 12 weeks
Ostatní jména:
|
|
Experimentální: Children with T1D 0.08 mg/kg SQ dose
Cohort 2 Group 1:0.08 mg/kg SQ dose for a total of 12 weeks |
Weekly siplizumab doses for a total of 12 weeks
Ostatní jména:
|
|
Experimentální: Children with T1D 0.12 mg/kg SQ dose
Cohort 2 Group 2:0.12 mg/kg SQ dose for a total of 12 weeks |
Weekly siplizumab doses for a total of 12 weeks
Ostatní jména:
|
|
Experimentální: Children with T1D 0.18 mg/kg SQ dose
Cohort 2 Group 3: 0.18 mg/kg SQ dose for a total of 12 weeks |
Weekly siplizumab doses for a total of 12 weeks
Ostatní jména:
|
|
Experimentální: Children with T1D 0.22 mg/kg SQ dose
Cohort 2 Group 4: 0.22 mg/kg SQ dose for a total of 12 weeks |
Weekly siplizumab doses for a total of 12 weeks
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of Participants With a T Cell Phenotype Signature Response
Časové okno: Week 0 to Week 12
|
A participant is defined as achieving a T Cell phenotype signature response if the participant experiences both a 75% increase or greater from baseline in the CD4 Treg/Tem ratio in blood and a 20% increase or greater from baseline in PD1+TIGIT+ frequency within circulating CD4 Tem. The two criteria will be evaluated at weeks 2, 4, 8, and 12. Both criteria do not need to be achieved at the same time point. |
Week 0 to Week 12
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Frequency of Adverse Events (AEs) in All Siplizumab Dosing Arms
Časové okno: From week 0 to week 100
|
AE will include any untoward medical occurrence associated with siplizumab administration or any study-mandated procedure. A treatment-emergent adverse event (TEAE) is defined as in increase in grade from baseline or from the last post-baseline value that doesn't meet grading criteria. |
From week 0 to week 100
|
|
Mixed Meal Tolerance Test (MMTT)-Stimulated Mean 2-hour C-peptide AUC
Časové okno: At Weeks 12, 24, 36, 52
|
C-peptide is released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The mixed meal tolerance test (MMTT) was performed in the morning, and blood samples for C-peptide were collected at baseline (pre-meal) and various minutes post-meal at each visit and analyzed by a central laboratory. C-peptide area under the curve (AUC) was calculated using the trapezoidal rule over the 2-hour time period. Larger numbers are better in these AUC results: more insulin being produced reflects less severe disease. The mean 2-hour C-peptide AUC, measured in nmol/L, is computed by dividing the total AUC by the length of the MMTT (e.g. 120 minutes). |
At Weeks 12, 24, 36, 52
|
|
Insulin Use (U/kg/Day)
Časové okno: At Weeks 6, 12, 24, 36 and 52.
|
Measured as U/kg body weight/day; participants recorded the type and amount of insulin they have used during the 5-day period immediately preceding the beginning of treatment, middle of treatment, end of treatment, and at all follow-up visits |
At Weeks 6, 12, 24, 36 and 52.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Studijní židle: Stephen Gitelman, M.D., University of California San Francisco, School of Medicine: Diabetes Center
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- DAIT ITN095AI
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
Časový rámec sdílení IPD
On average, within 24 months after database lock for the trial.
Kritéria přístupu pro sdílení IPD
Open access.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .